Data Readout

Kodiak's Phase 3 PINNACLE for KSI-101 targets BCVA gains in Q1 2027

The sham-controlled study will test whether an IL-6/VEGF bispecific can beat sham on vision gains in inflammatory macular edema, a mechanism with no resolved Phase 3 precedent in this population.

By AppliedXLJuly 13, 2026Trial NCT06996080

Executive Summary

Kodiak Sciences is running a registrational Phase 3 trial of an intravitreal IL-6/VEGF bispecific against sham in an inflammatory eye disease that lacks an approved disease-modifying treatment, with topline data guided for the first quarter of 2027.
The trial's enrollment target doubled and its completion timeline held nearly steady, a pattern consistent with a program that is filling on pace rather than one under operational strain.
The sponsor's own guidance on when data will post has moved across multiple quarters in successive disclosures, making the calendar itself, not the trial's conduct, the more uncertain variable heading into the window.
The mechanism has no resolved same-target Phase 3 precedent in this indication, so the readout will be the first data point establishing whether IL-6 and VEGF co-inhibition changes outcomes in a disease that currently has no approved disease-modifying option.

The trial

PINNACLE (NCT06996080) is a randomized, sham-controlled Phase 3 study of KSI-101, an intravitreal bispecific targeting interleukin-6 and VEGF, in patients with macular edema secondary to inflammation, or MESI. The trial enrolls patients with central subfield thickness between 320 and 400 microns and BCVA scores between 25 and 78 ETDRS letters, roughly 20/25 to 20/320 Snellen equivalent, with active or inactive non-infectious intraocular inflammation. The single registered primary endpoint is mean change in best corrected visual acuity (BCVA), a functional vision measure, against sham. Kodiak guided topline data for the first quarter of 2027 in a November 2025 disclosure, a window that runs from January 1 to March 31, 2027 and contains the trial's registered primary completion date of February 1, 2027. NCT06996080+1

Probability of Success

Endpoint Met40%

Completes52%

Clinical Significance25%

Regulatory66%

What changed operationally

Kodiak doubled PINNACLE's anticipated enrollment target from 150 to 300 patients on May 18, 2026, the same date it moved the primary completion date from December 1, 2026 to February 1, 2027, a two-month shift. Earlier, the trial moved from Not Yet Recruiting to Recruiting status in September 2025, roughly two months after its July 16, 2025 start date. An enrollment increase paired with a modest completion-date shift falls within the routine band for a trial of this size and design, not evidence of a program in distress. The company's November 2025 update described both PINNACLE and its companion Phase 3 study, PEAK, as enrolling at a faster-than-expected pace. NCT06996080+1

The guidance drift

The topline-timing message itself has moved across disclosures: an August 2025 communication pointed to fourth-quarter 2026 or first-quarter 2027 for the PEAK and PINNACLE program together, a November 2025 release narrowed PINNACLE specifically to first-quarter 2027, and subsequent disclosures in January, February, March and May 2026 pushed PINNACLE's topline guidance to second-quarter 2027. "Kodiak Sciences has entered a period of sustained momentum driven by compelling clinical data, accelerated execution and growing external enthusiasm...across all three of our late-stage programs," Kodiak Chief Executive Officer Victor Perlroth said in the November 2025 release announcing the Q1-2027 guidance. The trial itself has not slipped in status or enrollment terms; the calendar communicated to investors has moved instead. Kodiak

The competitive frame

No other sponsor is running a Phase 3 trial that shares KSI-101's target combination of interleukin-6 and VEGF in this indication; the only identified Phase 3 peer in macular edema secondary to inflammation is Kodiak's own companion study, PEAK (NCT06990399), which shares the sponsor and drug but not an independent mechanism test. That leaves PINNACLE without a resolved same-target precedent in this population to benchmark against. Kodiak has previously pointed to intraocular IL-6 inhibition data presented at the American Academy of Ophthalmology meetings as validating local IL-6 suppression's tolerability and effect on vision and anatomy in uveitic macular edema, a related condition, as scientific support for the mechanism. Absent a validated disease-modifying therapy in MESI itself, a BCVA gain over sham that holds as the trial matures toward its registered February 2027 completion date would be the result that establishes the mechanism's clinical relevance in this specific population. Kodiak

This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.